GlassScriptPhysician profile
James Douglas Gladden
NPI 1861831067
$9,024.43
in general payments reported to CMS, 2019-2025
25 companies · $584 in 2025
The $584 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,623 · 2022: $1,821 · 2023: $2,398 · 2024: $2,598 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,936 · Travel and Lodging: $2,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,936.08 |
| Travel and Lodging | $2,644.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $3,409.39 | 2021-2023 | Pascal |
| Abbott Laboratories | $2,871.60 | 2022-2024 | Mitraclip, Amplatzer Amulet, Coroflow |
| Medtronic, INC. | $632.06 | 2021-2025 | Symplicity G3, Corevalve Evolut R, Onyx Frontier |
| Boston Scientific Corporation | $356.01 | 2022-2024 | Eluvia |
| Siemens Medical Solutions USA, INC. | $306.86 | 2024 | Acuson Origin Diagnostic Ultrasound System, Artis Icono Floor |
| Ge Healthcare | $252.22 | 2023-2024 | |
| Pfizer INC. | $198.24 | 2024-2025 | |
| Inari Medical, INC. | $187.97 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| E.R. Squibb & Sons, L.L.C. | $160.92 | 2025 | Camzyos, Eliquis |
| Abiomed | $111.12 | 2024 | Impella |
| Novartis Pharmaceuticals Corporation | $81.36 | 2022-2025 | |
| Novo Nordisk INC | $74.04 | 2025 | Rybelsus, Ozempic |
| Angiodynamics, INC. | $66.08 | 2024-2025 | Alphavac |
| Kiniksa Pharmaceuticals International, Plc | $52.01 | 2024 | Arcalyst |
| Atricure, INC. | $49.02 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.48 | 2024-2025 | Jardiance |
| Chiesi USA, INC. | $33.03 | 2024-2025 | Kengreal, Cleviprex |
| Biosense Webster, INC. | $30.56 | 2025 | Nuvision Ice Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.36 | 2023-2024 | Lifevest |
| Amgen INC. | $18.72 | 2023 | Repatha |
| Merck Sharp & Dohme LLC | $17.49 | 2025 | Verquvo |
| Kiniksa Pharmaceuticals, LTD. | $17.28 | 2023 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $15.34 | 2024 | Farxiga |
| Terumo Medical Corporation | $14.62 | 2025 | Azur Cx Detachable, R2p Misago, Angio-Seal |
| Cardiovascular Systems INC. | $10.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gladden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.